M&T Bank’s Myriad Genetics MYGN Stock Holding History

M&T Bank’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-4,895	Closed	-$211K	–	1780
2015 Q4	$211K	Sell	4,895 -676	-12%	-$28.6K	﹤0.01%	1484
2015 Q3	$209K	Sell	5,571 -8,181	-59%	-$290K	﹤0.01%	1509
2015 Q2	$468K	Buy	13,752 +5,013	+57%	+$170K	﹤0.01%	1251
2015 Q1	$310K	Buy	8,739 +101	+1%	+$3.62K	﹤0.01%	1430
2014 Q4	$294K	Sell	8,638 -2,011	-19%	-$71.4K	﹤0.01%	1503
2014 Q3	$412K	Buy	10,649 +10,549	+10,549%	+$394K	﹤0.01%	1368
2014 Q2	$4K	Hold	100	–	–	﹤0.01%	1005
2014 Q1	$3K	Sell	100 -25	-20%	-$775	﹤0.01%	1080
2013 Q4	$3K	Sell	125 -4,920	-98%	-$124K	﹤0.01%	1019
2013 Q3	$119K	Buy	5,045 +4,920	+3,936%	+$140K	0.01%	475
2013 Q2	$3K	Buy	+125	New	+$3.62K	﹤0.01%	962

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

M&T Bank's MYGN Position: Q1 2016 in Review

M&T Bank sold out of Myriad Genetics (MYGN) in Q1 2016, closing a stake of 4,895 shares — an estimated $211K sold.

M&T Bank first reported a position in MYGN in Q2 2013 and held it in 11 quarters. The position peaked at $468K in Q2 2015. 233 funds tracked by Wall St. Rank hold MYGN as of Q1 2016.

M&T Bank reported no remaining Myriad Genetics position as of Q1 2016 after selling out during the quarter.
M&T Bank sold 4,895 Myriad Genetics shares in Q1 2016, an estimated $211K.
M&T Bank first reported a position in Myriad Genetics in Q2 2013 and held it in 11 quarters.
M&T Bank's Myriad Genetics position peaked at $468K in Q2 2015.
233 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2016.

Based on M&T Bank's 13F filing for Q1 2016, filed 11 May 2016.